Circular Ribonucleic Acid circFTO Promotes Angiogenesis and Impairs Blood-Retinal Barrier

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

1. Involvement of the miR-128-3p/KDM3A/NLRP3 Axis in High Glucose-Induced Inflammatory Injury in Retinal Endothelial Cells.The Kaohsiung journal of medical sciences · 2026
   Article
2. circFTO binding with IGF2BP2 regulates trophoblast cells proliferation, migration, and invasion while mediating m6A modification of CCAR1 mRNA in spontaneous abortion.BMC molecular and cell biology · 2025
   Article
3. Functions and application of circRNAs in vascular aging and aging-related vascular diseases.Journal of nanobiotechnology · 2025
   Review
4. Targeting PDGF/PDGFR Signaling Pathway by microRNA, lncRNA, and circRNA for Therapy of Vascular Diseases: A Narrow Review.Biomolecules · 2024
   Review
5. Circular RNAs in human diseases.MedComm · 2024
   Review
6. CircRNA HLCS regulates lens epithelial cell apoptosis via miR-338-3p/BPNT1 axis.International ophthalmology · 2024
   Article
7. The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control.British journal of cancer · 2023
   Review
8. Perspectives of circular RNAs in diabetic complications from biological markers to potential therapeutic targets (Review).Molecular medicine reports · 2023
   Article
9. Nutritional Factors: Benefits in Glaucoma and Ophthalmologic Pathologies.Life (Basel, Switzerland) · 2023
   Review
10. The impact of early RPE cell junction loss on VEGF, Ang-2, and TIMP secretion in vitro.Molecular vision · 2023
    Article
11. Noncoding RNAs Are Promising Therapeutic Targets for Diabetic Retinopathy: An Updated Review (2017-2022).Biomolecules · 2022
    Review
12. circFTO upregulates transforming growth factor-alpha through sponging miR-148a-3p to regulate high glucose-induced ARPE-19 cells injury.Bioengineered · 2022
    Article
13. MicroRNAs, Long Non-Coding RNAs, and Circular RNAs in the Redox Control of Cell Senescence.Antioxidants (Basel, Switzerland) · 2022
    Review
14. Circular RNAs in diabetes and its complications: Current knowledge and future prospects.Frontiers in genetics · 2022
    Review
15. Diabetic retinopathy: Involved cells, biomarkers, and treatments.Frontiers in pharmacology · 2022
    Review

Corrections and comments

• Retraction · 2025-11-17Concerns/Issues about Data · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Original Data and/or Images not Provided and/or not Available · Plagiarism of Image · Unreliable Data · Unreliable Results and/or Conclusions · · See also: https://pubpeer.com/publications/A07277CA8946F1F5D2055C3F48A4CF
• Retracted
  Retraction: Circular ribonucleic acid circFTO promotes angiogenesis and impairs blood-retinal barrier2025

Authors and funding

7 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as